Franklin Resources’s Apogee Therapeutics APGE Stock Holding History

Franklin Resources’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$48.2M	Sell	363,379 -42,159	-10%	-$3.8M	0.01%	695
2026 Q1	$34.1M	Sell	405,538 -45,464	-10%	-$3.3M	0.01%	772
2025 Q4	$34M	Sell	451,002 -279,759	-38%	-$17.6M	0.01%	769
2025 Q3	$29M	Sell	730,761 -121,770	-14%	-$4.65M	0.01%	833
2025 Q2	$37M	Sell	852,531 -23,545	-3%	-$896K	0.01%	726
2025 Q1	$32.7M	Buy	876,076 +9,888	+1%	+$382K	0.01%	739
2024 Q4	$39.2M	Buy	866,188 +5,199	+0.6%	+$265K	0.01%	691
2024 Q3	$48.1M	Sell	860,989 -144,481	-14%	-$6.92M	0.01%	618
2024 Q2	$39.6M	Sell	1,005,470 -29,910	-3%	-$1.45M	0.01%	622
2024 Q1	$68.8M	Sell	1,035,380 -54,400	-5%	-$2.38M	0.02%	472
2023 Q4	$30.4M	Buy	1,089,780 +92,423	+9%	+$1.85M	0.01%	650
2023 Q3	$21.2M	Buy	+997,357	New	+$22M	0.01%	725

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Franklin Resources's APGE Position: Q2 2026 in Review

Franklin Resources reduced its Apogee Therapeutics (APGE) stake by 10% in Q2 2026, selling an estimated $3.8M and leaving 363,379 shares worth $48.2M. The position accounts for 0.01% of the portfolio, ranked #695.

Franklin Resources first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. The position peaked at $68.8M in Q1 2024. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Franklin Resources held 363,379 shares of Apogee Therapeutics worth $48.2M as of Q2 2026.
Franklin Resources sold 42,159 Apogee Therapeutics shares in Q2 2026, an estimated $3.8M.
Apogee Therapeutics made up 0.01% of Franklin Resources's portfolio in Q2 2026, its #695 holding.
Franklin Resources first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
Franklin Resources's Apogee Therapeutics position peaked at $68.8M in Q1 2024.
289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Franklin Resources's 13F filing for Q2 2026, filed 13 Aug 2026.